High CSF thrombin concentration and activity is associated with an unfavorable outcome in patients with intracerebral hemorrhage.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
15
07
2020
accepted:
18
10
2020
entrez:
11
11
2020
pubmed:
12
11
2020
medline:
29
12
2020
Statut:
epublish
Résumé
The cerebral thrombin system is activated in the early stage after intracerebral hemorrhage (ICH). Expression of thrombin leads to concentration dependent secondary neuronal damage and detrimental neurological outcome. In this study we aimed to investigate the impact of thrombin concentration and activity in the cerebrospinal fluid (CSF) of patients with ICH on clinical outcome. Patients presenting with space-occupying lobar supratentorial hemorrhage requiring extra-ventricular drainage (EVD) were included in our study. The CSF levels of thrombin, its precursor prothrombin and the Thrombin-Antithrombin complex (TAT) were measured using enzyme linked immune sorbent assays (ELISA). The oxidative stress marker Superoxide dismutase (SOD) was assessed in CSF. Initial clot size and intraventricular hemorrhage (IVH) volume was calculated based on by computerized tomography (CT) upon admission to our hospital. Demographic data, clinical status at admission and neurological outcome were assessed using the modified Rankin Scale (mRS) at 6-weeks and 6-month after ICH. Twenty-two consecutive patients (9 females, 11 males) with supratentorial hemorrhage were included in this study. CSF concentrations of prothrombin (p < 0.005), thrombin (p = 0.005) and TAT (p = 0.046) were statistical significantly different in patients with ICH compared to non-hemorrhagic CSF samples. CSF concentrations of thrombin 24h after ICH correlated with the mRS index after 6 weeks (r2 = 0.73; < 0.005) and 6 months (r2 = 0.63; < 0.005) after discharge from hospital. Thrombin activity, measured via TAT as surrogate parameter of coagulation, likewise correlated with the mRS at 6 weeks (r2 = 0.54; < 0.01) and 6 months (r2 = 0.66; < 0.04). High thrombin concentrations coincide with higher SOD levels 24h after ICH (p = 0.01). In this study we found that initial thrombin concentration and activity in CSF of ICH patients did not correlate with ICH and IVH volume but are associated with a poorer functional neurological outcome. These findings support mounting evidence of the role of thrombin as a contributor to secondary injury formation after ICH.
Sections du résumé
BACKGROUND
The cerebral thrombin system is activated in the early stage after intracerebral hemorrhage (ICH). Expression of thrombin leads to concentration dependent secondary neuronal damage and detrimental neurological outcome. In this study we aimed to investigate the impact of thrombin concentration and activity in the cerebrospinal fluid (CSF) of patients with ICH on clinical outcome.
METHODS
Patients presenting with space-occupying lobar supratentorial hemorrhage requiring extra-ventricular drainage (EVD) were included in our study. The CSF levels of thrombin, its precursor prothrombin and the Thrombin-Antithrombin complex (TAT) were measured using enzyme linked immune sorbent assays (ELISA). The oxidative stress marker Superoxide dismutase (SOD) was assessed in CSF. Initial clot size and intraventricular hemorrhage (IVH) volume was calculated based on by computerized tomography (CT) upon admission to our hospital. Demographic data, clinical status at admission and neurological outcome were assessed using the modified Rankin Scale (mRS) at 6-weeks and 6-month after ICH.
RESULTS
Twenty-two consecutive patients (9 females, 11 males) with supratentorial hemorrhage were included in this study. CSF concentrations of prothrombin (p < 0.005), thrombin (p = 0.005) and TAT (p = 0.046) were statistical significantly different in patients with ICH compared to non-hemorrhagic CSF samples. CSF concentrations of thrombin 24h after ICH correlated with the mRS index after 6 weeks (r2 = 0.73; < 0.005) and 6 months (r2 = 0.63; < 0.005) after discharge from hospital. Thrombin activity, measured via TAT as surrogate parameter of coagulation, likewise correlated with the mRS at 6 weeks (r2 = 0.54; < 0.01) and 6 months (r2 = 0.66; < 0.04). High thrombin concentrations coincide with higher SOD levels 24h after ICH (p = 0.01).
CONCLUSION
In this study we found that initial thrombin concentration and activity in CSF of ICH patients did not correlate with ICH and IVH volume but are associated with a poorer functional neurological outcome. These findings support mounting evidence of the role of thrombin as a contributor to secondary injury formation after ICH.
Identifiants
pubmed: 33175864
doi: 10.1371/journal.pone.0241565
pii: PONE-D-20-21960
pmc: PMC7657554
doi:
Substances chimiques
Biomarkers
0
Thrombin
EC 3.4.21.5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0241565Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Neurosci. 2005 Apr 20;25(16):4082-90
pubmed: 15843610
Lancet. 2009 May 9;373(9675):1632-44
pubmed: 19427958
Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2264-9
pubmed: 10681455
Acta Neurochir Suppl. 2008;105:47-50
pubmed: 19066081
J Neurotrauma. 2020 Jun 15;37(12):1481-1490
pubmed: 31830857
Biol Chem. 2003 Feb;384(2):193-202
pubmed: 12675511
Acta Neurochir (Wien). 1998;140(6):579-84
pubmed: 9755325
J Neurochem. 2003 Jan;84(1):3-9
pubmed: 12485396
J Mol Cell Cardiol. 2018 Sep;122:80-87
pubmed: 30098988
Br Med Bull. 2000;56(2):444-56
pubmed: 11092093
J Clin Invest. 2003 Jan;111(1):25-7
pubmed: 12511583
Endocr Rev. 2005 Feb;26(1):1-43
pubmed: 15689571
Brain Res Mol Brain Res. 1991 Oct;11(3-4):355-8
pubmed: 1661827
FEBS Lett. 1999 Dec 17;463(3):387-9
pubmed: 10606759
Neurosurg Focus. 2003 Oct 15;15(4):E6
pubmed: 15344899
J Clin Oncol. 2009 May 1;27(13):2302-3; author reply 2303-4
pubmed: 19332721
J Neurosci. 1995 Jul;15(7 Pt 2):5389-401
pubmed: 7623161
Neurosurgery. 2006 Mar;58(3):542-50; discussion 542-50
pubmed: 16528196
Int Immunopharmacol. 2019 Jul;72:473-478
pubmed: 31039464
Stroke. 1997 Sep;28(9):1666-70
pubmed: 9303007
Neurochem Res. 2015 Nov;40(11):2220-9
pubmed: 26342829
Thromb Haemost. 1997 Dec;78(6):1473-9
pubmed: 9423797
N Engl J Med. 2001 May 10;344(19):1450-60
pubmed: 11346811
Physiol Rev. 2004 Apr;84(2):579-621
pubmed: 15044683
Neurocrit Care. 2020 Jul 1;:
pubmed: 32613425